title: Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnoea activity in patients with essential hypertension and OSA.
abstract: OBJECTIVE
  To investigate the effect of nebivolol, a third generation beta-blocker, on blood pressure (BP) reduction and polysomnographic parameters in hypertensive patients with mild-to-moderate obstructive sleep apnoea (OSA).
  
  
  METHODS
  In this double-blind, parallel group study, patients were randomized to nebivolol 5 mg or valsartan 80 mg once daily following a 14-day, placebo run-in period during which any antihypertensive medication were discontinued. BP and heart rate measurements and overnight polysomnography were performed at baseline and after 6 weeks of treatment. Safety and tolerability were assessed.
  
  
  RESULTS
  Thirty-one patients were randomized to nebivolol (n = 16) or valsartan (n = 15). After six weeks both systolic and diastolic BP were effectively reduced by both treatments. Reductions in BP were not statistically significant different between agents, but mean heart rate was significantly decreased with nebivolol (compared with valsartan (p < 0.001). There was no statistically significant difference between both treatments for the change from baseline to treatment end for mean (+/-SD) Apnoea Hypopnoea Index (AHI) (nebivolol: 23.0 +/- 9.2 to 27.9 +/- 21.2 events/h; valsartan: 23.8 +/- 6.6 to 22.5 +/- 18.0 events/h; p = 0.48) or for any other sleep-related parameters. Both agents were well tolerated.
  
  
  CONCLUSIONS
  Nebivolol has a significant BP reduction effect in patients with OSA that is similar to valsartan and reduces heart rate to a greater extent which may prove beneficial in selected patients.
authors.affiliation: Philipps-University Marburg, Marburg, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Heitmann
authors.forename: T
authors.initials: T
authors.lastname: Greulich
authors.forename: C
authors.initials: C
authors.lastname: Reinke
authors.forename: U
authors.initials: U
authors.lastname: Koehler
authors.forename: C
authors.initials: C
authors.lastname: Vogelmeier
authors.forename: H F
authors.initials: HF
authors.lastname: Becker
authors.forename: A C
authors.initials: AC
authors.lastname: Schmidt
authors.forename: S
authors.initials: S
authors.lastname: Canisius
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage* / Q000009:adverse effects; D001578:Benzopyrans / Q000008:administration & dosage* / Q000009:adverse effects; D001794:Blood Pressure / Q000187:drug effects; D004983:Ethanolamines / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol; D017286:Polysomnography; D012891:Sleep Apnea Syndromes / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D013777:Tetrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014633:Valine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000068756:Valsartan
chemical_list: D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D001578:Benzopyrans; D004983:Ethanolamines; D013777:Tetrazoles; D000068577:Nebivolol; D000068756:Valsartan; D014633:Valine